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Objective: To study the effect of comorbidity on the course 
of physical functioning in patients after stroke and with 
multiple sclerosis.
Subjects: Patients after a first-ever supratentorial stroke 
(n = 198), who had been admitted for inpatient rehabilitaion, 
and patients with recently diagnosed multiple sclerosis 
(n =146).
Design: Prospective, observational study over a period of 3 
years.
Measurements: Physical functioning was measured with the 
motor score of the Functional Independence Measure at 
baseline (time of diagnosis), and at 6 months, and 1 and 3 
year follow-ups. Cardiovascular, respiratory, musculoskele-
tal, diabetes mellitus, and other comorbidities were meas-
ured at baseline. 
Results: Patients after stroke and multiple sclerosis with 
comorbidity showed a significantly lower level of physical 
functioning over all 4 measurements. There was no differ-
ence in the course of physical functioning between patients 
after stroke with and without comorbidity. In patients with 
multiple sclerosis, a greater decrease in physical functioning 
over the 3-year follow-up was found in patients with comor-
bidity of the musculoskeletal system compared with patients 
without. 
Conclusion: These findings indicate that similar improve-
ments in physical functioning can be expected during reha-
bilitation of stroke patients with comorbidity compared with 
patients without these conditions. In patients with multiple 
sclerosis, musculoskeletal comorbidity requires further at-
tention because of its association with a greater decrease in 
physical functioning.
Key words: comorbidity, functional outcome, neurological dis-
orders, rehabilitation.
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INTRODUCTION
Comorbidity is a complex phenomenon that is considered to 
affect the course and outcome of the rehabilitation process 
(1). It refers to the existence of a set of chronic conditions 
present in patients with a particular (index) disease, which 
are not directly related to this index disease (2, 3). In general, 
comorbidity has been shown to have a negative impact on 
functional status and quality of life, and leads to a higher use 
of healthcare services (3, 4). 
It is well established that comorbidity has a negative impact 
on the level of physical functioning in patients with neurologi-
cal disorders (1, 5–9), and that the occurrence of comorbidity 
varies by disease group and the severity of the disease (10). 
Comorbidity may be an important predictor of rehabilitation 
outcome, and may, as such, affect the planning of treatment 
and resources. However, despite the obvious difference in 
functioning between neurological patients with and without 
comorbidity, little is known about the influence of comor-
bidity on the course of functioning of neurological patients, 
especially in the longer term. Inconsistent results have been 
reported in studies investigating the effect of comorbidity on 
the course of functioning (recovery) in stroke rehabilitation 
(6, 9, 11, 12). Some studies found a negative impact of co-
morbidity on functional gain (improvements in functioning 
expressed per day) during rehabilitation (9, 11, 12), while 
another study reported no effects (6). In the longer term also, 
in the post-rehabilitation period, no effect of comorbidity was 
reported (9). Multiple sclerosis (MS) is, in contrast to stroke, 
a progressive neurological disease with an expected decline 
in functioning over years. Although comorbidity is expected 
to affect the course of functioning in patients with MS, the 
relationship between comorbidity and physical functioning 
has, to our knowledge, not been investigated in this patient 
group. 
The purpose of the current study was to evaluate the effect 
of comorbidity on the course of physical functioning in pa-
tients with stroke and with MS over a period of 3 years after 
the diagnosis.
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METHODS
Subjects and design 
This project was carried out as part of a prospective study on func-
tional prognosis in neurological disorders (the FuPro-study). Patients 
with a first-ever supratentorial stroke, who had been admitted for 
inpatient rehabilitation, and patients with a recently diagnosed MS 
(< 6 months after diagnosis) participated in this study. The study was 
approved by the medical ethical committees of the University Medical 
Center in Utrecht (stroke), and the VU University Medical Center in 
Amsterdam (MS).
Measurements 
Physical functioning was measured with the motor score of the Func-
tional Independence Measure (FIMTM) (13, 14). The FIMTM measures 
the degree of disability by measuring the level of independence in basic 
activities of daily living. The FIM motor scale consists of 13 items. 
Each item measures the level of dependency on a 7-point scale, ranging 
from complete dependence (score 1) to complete independence (score 
7). Consequently, the FIM motor sum score ranges from 13 (complete 
dependence) to 91 (complete independence). Measurements were 
performed at baseline (time of the diagnosis or within 6 months), and 
at 6 months and 1- and 3-year follow-ups (after baseline). 
Comorbidity was measured at baseline in both groups. In the stroke 
group, patients were asked if they had comorbidities in the follow-
ing domains: cardiovascular, respiratory, musculoskeletal, diabetes 
mellitus, and other comorbidity. The answer (comorbidity “yes” or 
“no”) was registered for each domain. In the MS group, comorbidity 
was measured with the Cumulative Illness Rating Scale (CIRS) (15). 
The 13 CIRS items were converted to the comorbidity domains in the 
stroke group (see above). A CIRS score of 1 and higher was defined 
as having comorbidity. For both groups, the presence of comorbidity 
(comorbidity total) was reported as a dichotomous variable, defined 
as having comorbidity on at least 1 of the above-described domains, 
or not. Severity of MS was measured at baseline with the Expanded 
Disability Status Scale (EDSS) (16), and in patients after stroke with 
the Barthel Index (17).
Statistical analysis
The effect of comorbidity on the course of physical functioning was 
analysed in each patient group separately, using analysis of variance 
(ANOVA) for repeated measures, with the 4 repeated measures of the 
FIM motor score as dependent variables. The interactions between 
comorbidity and time (using the 4 repeated measurements) were evalu-
ated. Two separate analyses were performed, using total comorbidity 
(having comorbidity “yes” or “no”), as independent variable in the 
first analysis, and using the 5 comorbidity domains (cardiovascular, 
respiratory, musculoskeletal, diabetes, other comorbidity) as independ-
ent variables in the second analysis. A Greenhouse-Geisser (GG) cor-
rection of the degrees of freedom was applied in case the assumption 
of sphericity was not fulfilled. All analyses were adjusted for age and 
severity of the disease by including these variables as covariates in 
the repeated measures analyses.
RESULTS 
In the stroke group 265 patients were measured at baseline. Sev-
en patients died within the first year, 12 patients had a recurrent 
stroke and were excluded from follow-up, 20 patients withdrew 
from the study or could not be traced. Nine patients had missing 
values for comorbidity and 19 patients missed one of the FIMTM 
measurements, resulting in a complete data-set for 198 patients. 
In the MS group, 156 patients were measured at baseline. Seven 
patients were lost to follow-up because they withdrew from the 
study and 3 patients had missing data on comorbidity or FIMTM, 
resulting in a complete data-set for 146 patients. 
Baseline characteristics are shown in Table I. Patients 
with comorbidity were significantly older compared with pa-
tients without comorbidity in both stroke (p = 0.015) and MS 
(p = 0.032) groups. There was no significant difference in gender 
distribution between patients with and without comorbidity in 
both groups. Severity of the disease, measured with the Barthel 
Index at admission in the rehabilitation centre, showed no dif-
ferences between groups in patients after stroke (p = 0.227). 
Patients with MS with comorbidity were more severely affected 
(had a higher EDSS score) than those without (p < 0.001).
The frequency distribution of the comorbidity domains is 
listed in Table II. In the stroke group, 118 out of 198 (60%) 
patients reported any type of comorbidity. In the MS group, 65 
out of 146 (40%) patients reported any type of comorbidity. 
For patients with and without comorbidity, the 3-year course 
of physical functioning, expressed by the FIM motor scores 
are shown in Fig. 1a (stroke) and 1b (MS). FIM motor scores 
changed significantly over 3 years in both groups (p < 0.001), 
showing an initial improvement in stroke patients (in the first 6 
months), followed by a stabilization of functioning, and a small 
gradual decrease over 3 years in the patients with MS.
Table I. Characteristics of patients after stroke and patients with multiple sclerosis ( MS) at baseline
Stroke (n = 198) MS (n = 146)
No comorbidity
(n = 80)
With comorbidity
(n = 118)
No comorbidity
(n = 81)
With comorbidity
(n =65)
Gender, men, n (%) 42 (53) 74 (63) 27 (33) 25 (38)
Age, years, mean (SD) [range] 56.5 (10.5) [30–75] 60.2 (10.6) [30–82] 35.9 (9.5) [17–57] 39.3 (9.6) [23–60]
EDSS, median (25–75 percentile) – – 2.0 (1.5–3.0) 2.5 (2.0–3.5)
BI, median (25–75 percentile) 15 (10–19) 13 (10–17) – –
EDSS: Expanded Disability Status Scale; BI: Barthel Index; SD: standard deviation.
Table II. Number of patients for each comorbidity domain, measured 
at baseline in the stroke and multiple sclerosis (MS) group
Comorbidity at baseline*, n (%) Stroke (n = 198) MS (n = 146) 
Cardiovascular 93 (47) 7 (5)
Respiratory 13 (7) 8 (6)
Musculoskeletal 8 (4) 20 (14)
Diabetes 23 (12) 6 (4)
Other 99 (50) 44 (43)
Comorbidity total 118 (60) 65 (44)
*Stroke: at admission to inpatient rehabilitation; MS: within 6 months 
after definite diagnosis.
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The longitudinal analysis, adjusted for severity of the dis-
ease and age, showed that patients with comorbidity (total) 
had a significantly lower level of physical functioning com-
pared with those without comorbidity in both groups (stroke: 
F(1,194) = 3.95, p = 0.048, MS: F(1,142) = 7.62, p = 0.007). 
Total comorbidity was, however, not related to the course 
of physical functioning in both stroke (F(3,582) = 0.22, 
p = 0.823, GG-epsilon = 0.74) (Fig. 1a) and patients with MS 
(F(3,426) = 2.22, p = 0.113, GG-epsilon = 0.64) (Fig. 1b), when 
adjusted for age and severity of the disease (Table III).
In the stroke group, no significant effects on the course of 
physical functioning were found when all comorbidity domains 
were included in the analysis (cardiovascular: F(3,570) = 1.81, 
p = 0.160, respiratory: F(3,570) = 0.20, p = 0.895, musculoskel-
etal: F(3,570) = 0.18, p = 0.855, diabetes: F(3,570) = 1.46, 
p = 0.232, other comorbidity: F(3,570) = 1.30, p = 0.274, GG-
epsilon = 0.73) (Table III). When all 5 comorbidity domains 
were included in the analysis of the MS group, there was a 
significant effect of comorbidity of the musculoskeletal system 
domain on the course of motor functioning, showing a greater 
decrease in physical functioning in patients having comorbidity 
after 3 years’ follow-up (F(3,414) = 5.50, p = 0.005, GG-epsi-
lon = 0.64). The other comorbidity domains had no significant 
effect on the 3-year course of physical functioning (cardiovas-
cular: F(3,414) = 0.18, p = 0.832, respiratory: F(3,414) = 1.71, 
p = 0.184, diabetes: F(3,414) = 1.38, p = 0.252, other comorbid-
ity: F(3,414) = 0.36, p = 0.689, GG-epsilon = 0.64) (Table III). 
Based on the estimated means of the ANOVA for repeated 
measured, a decline in physical functioning of (approximately) 
5 points on the FIMTM was found in patients with MS with 
musculoskeletal comorbidity, compared with a decline of 2 
points in patients without these conditions (Fig. 2). The analy-
sis in both the stroke and MS group were adjusted for age and 
disease severity (Table III).
DISCUSSION 
The results of this study showed that comorbidity, existing 
early in the disease process, did not affect the 3-year course of 
physical functioning in stroke patients, while comorbidity of 
Fig. 1. Course of physical 
functioning (measured with 
Functional Independence 
Measure (FIM) motor score) 
in patients after (a) stroke and 
with (b) multiple sclerosis 
(MS), with and without co-
morbidity (raw data are pre- 
sented).
Table III. Results of analysis of variance for repeated measures for patients after stroke and multiple sclerosis (MS), with Functional Independence 
Measure (FIM) motor outcomes at baseline, after 6 months and after 1 and 3 years as dependent variables
Independent variables
Crude model (no adjustments) Adjusted for age and disease severity
F df p-value
Partial eta 
squared F df p-value
Partial eta 
squared
Stroke total comorbidity
t × comorbidity total 0.20 3, 588 0.812a 0.001 0.22 3, 582 0.823b 0.001
Stroke comorbidity domains
t × comorbidity cardiovascular
t × comorbidity respiratory
t × comorbidity musculoskeletal 
t × comorbidity diabetes mellitus
t × comorbidity other
1.31
0.47
1.57
2.17
1.11
3, 576
3, 576
3, 576
3, 576
3, 576
0.271a
0.616a
0.210a
0.118a
0.328a
0.007
0.002
0.008
0.011
0.006
1.81
0.20
0.18
1.46
1.30
3, 570
3, 570
3, 570
3, 570
3, 570
0.160c
0.895c
0.855c
0.232c 
0.274c
0.009
0.001
0.001
0.008
0.007
MS total comorbidity
time × comorbidity total 3.33 3, 432 0.040d 0.023 2.22 3, 426 0.113a 0.015
MS comorbidity domains
t × comorbidity cardiovascular
t × comorbidity respiratory
t × comorbidity musculoskeletal 
t × comorbidity diabetes mellitus
t × comorbidity other
0.11
1.33
5.64
1.32
0.98
3, 420
3, 420
3, 420
3, 420
3, 420
0.894e
0.265e
0.004e
0.293e
0.377e
0.001
0.009
0.039
0.009
0.007
0.18
1.71
5.50
1.38
0.36
3, 414
3, 414
3, 414
3, 414
3, 414
0.832a
0.184a
0.005a
0.252a
0.689a
0.001
0.012
0.038
0.010
0.003
df: degrees of freedom; t: measurements over time (baseline, after 6 months and after 1 and 3 years); a: Greenhouse-Geisser (GG) correction is 
applied with epsilon = 0.64; b: GG-epsilon = 0.74; c: GG-epsilon = 0.73; d: GG-epsilon = 0.63; e: GG-epsilon = 0.65.
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the musculoskeletal system did show a small, but significant, 
negative effect on the course of functioning in patients with 
MS. Obviously, there was an association between comorbid-
ity and the overall level of function in both groups, which is 
consistent with previous studies in patients after stroke (5, 6, 
9). The lack of effect of comorbidity on the course of function-
ing in patients after stroke, despite a clear relationship with 
the level of functioning, is in agreement with Giaquinto (6). 
They also found no effect of comorbidity on recovery during 
rehabilitation in stroke patients, measured with the FIMTM, 
and reported a correlation between comorbidity and FIMTM 
score both at admission and discharge of rehabilitation. Also 
Studenski et al. (9) found no relationship between comorbidity 
and changes in physical functioning in the post-rehabilitation 
period, using other indicators of physical functioning (Barthel 
Index, instrumented activities of daily living (IADL) and physi-
cal functioning scale). However, results were in contrast with 
other studies (11, 12) investigating the gain in functioning 
during rehabilitation, using FIMTM score improvements, or 
rehabilitation efficiency (FIMTM scores divided by the length 
of stay). An important difference between our study and most 
studies on comorbidity in stroke patients is that the latter in-
vestigated changes in functioning during rehabilitation, while 
in our study, patients were measured at fixed follow-up periods 
(at 6-months, 1- and 3-years), irrespective of the duration of 
the inpatient rehabilitation period. 
The results of the current study indicate that patients with 
MS with comorbidity of the musculoskeletal system have 
a greater decline in physical functioning compared with 
patients with MS without these conditions. Although this 
effect is rather small (a 3 point greater decline on the FIM 
motor score), it seems a relevant difference when compar-
ing it with the overall decline in physical functioning in the 
whole group. However, also at 3 years after the diagnosis 
the mean level of functioning is relatively high in the MS 
group. The greater decline in the last 2 years of the study 
shows that musculoskeletal problems are likely further to 
affect the course of physical functioning in the longer term. 
Given the mild status of the disease at the time of comorbidity 
measurement (baseline: within 6 months after the diagnosis), 
it might be expected that the comorbidity rate will increase 
with the duration of the disease. Musculoskeletal comorbid-
ity was the most frequently reported type of comorbidity in 
the MS group (except for the “other comorbidity” category) 
with a percentage of 14%, which was similar to a previous 
study reporting a percentage of around 10% (10). Although 
the clinical relevance of the findings need to be confirmed 
in future studies, results suggest that clinicians should notice 
musculoskeletal problems in patients with MS.
The focus of this study was to investigate the effect of 
comorbidity at the onset of the disease, in order to be able to 
predict the effect on long-term outcome. However, the level 
of functioning might also be influenced by combinations of, or 
additional comorbid conditions that appeared during the course 
of 3 years. A cross-sectional study in a large group of chronic 
disease patients revealed a synergistic effect of comorbid-
ity on physical and mental functioning (4). Due to the small 
sample size we were not able to take into account the effect 
of the combination of different types of comorbidity on the 
course of functioning. Another limitation of the present study 
is that only the effect of comorbidity on physical functioning 
is reported, while effects on social and cognitive functioning 
may also be expected. Although the FIMTM cognitive domain 
was also measured in the present study, the high level of 
cognitive functioning resulted in large ceiling effects on the 
FIMTM cognitive score for both groups, making meaningful 
analysis impossible. 
Comparison of comorbidity research is hampered by the 
variation in methods that are used to measure comorbidity (18). 
We used the CIRS in the MS group and converted these data 
to the predefined domains that were measured in the stroke 
group. This procedure may have limited the comparison with 
former studies. Nevertheless, the results did not change for the 
MS group when using the original CIRS score in the analysis 
(results not shown). In addition, comparison with other studies 
may be hampered by differences in outcome measures to meas-
ure physical functioning. Although the FIMTM is often used, 
most studies reported the total FIMTM score, which combines 
the physical and cognitive domains, thus limiting the conclu-
sions on each of the domains. Finally, differences in character-
istics of the study population, such as severity of the disease 
and age, may also be responsible for the conflicting findings in 
the literature. For this reason, all analyses in the present study 
were adjusted for age and severity of the disease.
It is concluded that, although a lower level of physical 
functioning was found in patients with comorbidity in both 
patients after stroke and patients with MS, comorbidity did 
not affect the course of physical functioning in patients after 
stroke, while patients with MS with comorbidity of the mus-
culoskeletal system showed a less favourable course. Although 
the clinical relevance of the latter findings, as well as the ef-
fects of musculoskeletal comorbidity on the longer term should 
be further investigated, results indicate that musculoskeletal 
problems should be taken into account when planning treat-
ment in patients with MS.
Fig. 2. Course of physical functioning for patients with multiple sclerosis 
(MS) with and without comorbidity of the musculoskeletal system. 
Estimated means from the repeated measures analysis of variance are 
presented. 
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